CTN endorsed studies and how to apply

Endorsement of a clinical trial by the ANZCA CTN is a powerful badge of quality, adding to the competitiveness of studies in peer-reviewed grant processes, the acceptability of protocols to ethics committees, investigators and study participants, and the attractiveness of completed projects to journal editors and scientific meeting convenors.

Purpose of CTN Endorsement

The purposes of the ANZCA CTN endorsement process are to:

  • promote a high standard of clinical trial design, conduct, analysis and reporting
  • increase the competitiveness of grant applications of endorsed clinical trials
  • strengthen the brand of the ANZCA CTN and its endorsed clinical trials
  • encourage participation in endorsed clinical trials by ANZCA CTN-affiliated sites and investigators
  • encourage investigators to use the resources of the CTN office for their clinical trials.

Types of studies that will be considered for CTN endorsement

Applications for ANZCA CTN endorsement will be considered for:

  • Large multi-centre clinical trials in the field of, or related to, anaesthesia, perioperative and pain medicine, that will involve CTN members and/or the CTN office and resources, to promote the study, source sites and investigators, hold investigator and committee meetings or house a trial manager for the project.
  • Single centre or multi-centre feasibility and pilot trials, or other preparatory or observational studies in the field, which are intended to lead to a future ANZCA CTN endorsed large multicentre clinical trial.

Final decisions about the eligibility of an application will be made by the CTN Executive Chair.

Eligibility for endorsement

Applications should come from ANZCA fellows and/or trainees and affiliated investigators who are closely involved with the planning and conduct of the trial. They will likely be named on the protocol of the trial, be members of the trial committees and/or be named investigators on peer reviewed grant applications. It is recognised that trial governance and titles of roles within the trial governance structure vary. If the role of the applicant is unclear, then the chair of the CTN will decide if the applicant has a sufficiently substantive role in the trial governance.

ANZCA/FPM trainees who apply for CTN endorsement must identify a supervisor among the other investigators who is acceptable to the CTN Executive.

Applications from investigators who are not ANZCA/FPM fellows or trainees will be considered at the discretion of the CTN Executive chair. Suitable applications would be those that foster collaboration between the ANZCA CTN and other trial networks locally and internationally.

The application

Applications for ANZCA CTN endorsement will be made on the approved application form and include a covering letter explaining why their trial should be considered for endorsement. Submitted applications will be checked by the ANZCA CTN Manager and incomplete applications will be returned to the applicants. Study protocols for ANZCA CTN endorsement will be developed in accordance with ICH GCP Guidelines and include:

  • The membership of the trial steering committee and administering institution(s)
  • The aims of the study and hypotheses to be tested
  • A detailed literature review including references
  • A detailed research plan
  • The proposed budget
  • The funding strategy
  • Assessment of study size, power, timeline and feasibility
  • Demonstration of in-principle support from participating sites
  • Consideration of all relevant ethical issues

The review process

The CTN Executive chair or his/her nominee will identify two individuals to undertake a review of the application, including at least one reviewer who is a member of the CTN Executive. The reviewers will provide a written report that may include questions, comments and/or suggestions for improvement. The turnaround time for the initial review is 20 working days from receipt of a complete application. Applicants are allowed two weeks to respond to the reviewers’ reports. The reviewers then provide a written recommendation to the CTN Manager regarding endorsement of the study. In the case of a disagreement between the reviewers, the application will be considered by the full CTN Executive.

Trial investigators seeking CTN endorsement prior to applications for grant funding, ethics approvals or other deadlines, are expected to provide adequate notification of intention to submit, with due consideration of the impact of such things as holiday periods on availability of suitable reviewers prior to submission deadlines. Expedited reviews to meet study-related deadlines may be considered but are not guaranteed. Investigators are strongly advised to seek CTN endorsement before the initial grant application rather than during the grant review process or after the trial has commenced.

If a submission for endorsement is rejected the applicant may seek reconsideration or review of the decision, or appeal the decision, under ANZCA regulations.

Presentation at an ANZCA CTN Strategic Research Workshop

Applicants are strongly encouraged to present their proposal at an ANZCA CTN Strategic Research Workshop. Initial presentation at an early stage of development and re-presentation of refined proposals at subsequent meetings are strongly encouraged. Presenters will be asked to identify their intention to seek endorsement when they submit their abstracts for the Workshop. This will allow the CTN Executive Chair or his/her nominee to identity two reviewers who will be present at the Workshop to take notes that will inform the review process. Presentation at an ANZCA CTN Strategic Research Workshop is not an alternative to a written application.

Conditions of endorsement

The trial steering committee is responsible for obtaining resources and conducting the study in accordance with endorsed protocol and in compliance with ANZCA policy and codes of research conduct (e.g. the Australian Code for the Responsible Conduct of Research produced by the NHMRC), including obtaining approval for the study from a recognised ethics committee. The CTN Executive will consider the strategic objectives of the CTN and optimal deployment of CTN resources when considering applications for trial endorsement. Considerations of such things as appropriateness of research question and methodology, public interest, and competing priorities among investigators and studies, will be made. The CTN Executive will retain to discretion to endorse or not endorse protocols based on these considerations.

Endorsement of a pilot study does not mean automatic endorsement of a subsequent full study. Endorsement of a full study does not mean endorsement of subsequent sub-studies and post hoc analyses. A progress report, in the form of a presentation at the ANZCA CTN Strategic Research Workshop, must be offered annually.

CTN Executive reserves the right to withdraw endorsement at any stage should the study not progress adequately, if it is not being conducted in accordance with these conditions, or if irresolvable conflicts of interest arise.

Trial funding considerations

Investigators must not indicate in a grant application that the study is endorsed by the CTN unless formal endorsement has been provided in writing by the CTN Executive.

NHMRC funding: Applications for CTN endorsement of trials from investigators intending to apply for NHMRC grants in the next upcoming funding round are required to submit their protocols including core data set plans to the CTN Office prior to the last meeting of the CTN Executive for the calendar year, for consideration by the Executive, or formal endorsement may not be considered prior to funding application deadlines. Late applications under extraordinary circumstances or for funding to be sought outside the NHMRC funding cycle e.g. MRFF calls for submission, will be considered at the discretion of the CTN Chair. Commercial funding: Financial or in-kind support from commercial entities may be acceptable, but only if the trial steering committee retains complete and enduring scientific independence and ownership of data and intellectual property. This must be established in a contract or agreement with the commercial entity. The CTN Executive may reconsider endorsement if such contracts and agreements are signed which were not part of the original proposal.

CTN office support packages and funding models

Various levels of office support are available to principal investigators (PI) of CTN endorsed trials.

The CTN office has developed a document outlining support packages and funding models available to chief investigators of endorsed trials. This will allow investigators to adequately budget trial specific support from the CTN office in their grant application before they submit their grant application.

CTN Endorsement for large multicentre trials where substantial grants are being sought from funding bodies will require appropriate financial support for the CTN office in their budget. The level of support should reflect the expected level of involvement of the CTN Office in the trial, which includes support and mentorship for principal investigators, trial managers, and site investigators and coordinators, assistance with ethics and site governance submissions, site initiation, and access to the CTN mailing list and promotion of the trial throughout the College (e-news, bulletin, ad-hoc reports, promotional material, ANZCA ASM and Research Foundation).


Applicants will need to contact the CTN manager to get a copy of the full endorsement guidlelines and application form, and to discuss CTN office level of support and budget.  

Applicants will need to send a copy of the completed application form and a copy of their CV to [email protected].

CTN endorsed studies

The CTN developed the first endorsement guidelines in 2012 and officially began endorsing studies in 2013.  Explore the studies we have endorsed over the decade. 

Endorsed studies

Professor Robert Sanders (NSW)

DECIDE study: Dexmedetomidine in Cardiac surgical Intraoperative Drug Evaluation

Dr Luke Perry (Vic)

Pulmonary catheters in adults undergoing low risk cardiac surgery (The PUMA Pilot): a multicentre, randomised, controlled, consumer co-designed, Vanguard, pilot and feasibility clinical trial

Dr David Sturgess and Dr Judy Munday (QLD)

The Glow Trial: Implementing Guidelines for hypothermia prevention with Local adaptation to keep periOperative patients Warm

Dr Daniel Frei (NZ) The HOT-ROX trial: The Hospital Operating Theatre- Randomised OXygen trial 2022
Professor Trisha Peel (Vic) CALIPSO trial: The Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study 2022
Professor Kate Leslie (AO) (Vic) The SNAPP study: Suggamedex, Neostigimine and Postoperative Pulmonary Complications 2020
Dr Benjamin Moran (NSW) The PAIN-ICU Study: PAIN in Survivors of Intensive Care Units. A prospective, multi-centre observational Cohort study to determine the incidence, risk factors and impact of chronic pain in critically ill adult patients discharged from ICU 2020
Professor Paul Myles (Vic) Prevalence of Asymptomatic SARS-Cov-2 Infection in Elective Surgical Patients in Australia: a prospective cohort study. 2020
Dr Raymond Hu (Vic) TRICS IV trial: Restrictive versus Liberal Transfusion in Younger Patients Undergoing Cardiac Surgery. 2019

Associate Professor Susan Humphreys (Qld)

HAMSTER trial: High-flow oxygen for children’s airway surgery: A randomised controlled trial. 2019

Professor Paul Myles (Vic)

DECS-II trial: Comparative effectiveness of dexamethasone for cardiac surgery 2019
Professor Michael Reade (QLD)

CLIP-II: Cryopreserved vs. Liquid Platelets trial

Professor Paul Myles (Vic)

TRIGS trial: Tranexamic acid to Reduce Infection after Gastrointestinal Surgery

Dr Thomas Painter (SA)

POISE-3 Trial: PeriOperative ISchemic Evaluation-3

Professor Tomás Corcoran (WA)

LOLIPOP: Lidocaine and chronic post-surgical pain in breast cancer surgery

Professor Bernhard Riedel (Vic)

VAPOR-C Study: Volatile Anaesthesia and Perioperative Outcomes Related to Cancer

Associate Professor Gordon Doig (NSW)

Intravenous amino acid therapy for kidney protection in cardiac surgery patients: a multicentre randomised controlled trial.”

Dr Doug Campbell (NZ)

MASTERSTROKE: Management of Systolic blood pressure Thrombectomy by Endovascular Route for acute ischaemic STROKE

Associate Professor David Canty (Vic)

ECHONOF III trial: A pragmatic multicentre randomised trial of focused cardiac ultrasound prior to surgery for hip fracture.

Associate Professor Lachlan Miles (Vic)

NATO study: Non-Anaemic Iron Deficiency and Tranfusion Outcomes after Colorectal Cancer Surgery

Associate Professor Jai Darvall (Vic)

Chewy: A randomised non-inferiority trial of chewing gum versus ondansetron to treat postoperative nausea and vomiting in female patients after breast and laparoscopic surgery.

Professor Yahya Shehabi (Vic)

Perioperative Dexmedetomidine in High Risk Cardiac Surgery Evaluation - DiCE II Trial; Muliticenter Multinational Randomised Double Blind Placebo Controlled Trial.

Dr Ianthe Boden (Tas)

CHESTY: (CHEST infection prevalence following surgerY) – an international multicenter observational trial.

Professor Guy Ludbrook (SA)

Advanced Recovery Care

Dr Nico Terblance (Tas)

PADDI-Hypothalamus Pituitary Adrenal Axis Sub-Study.

Professor Philip Peyton (Vic)

ROCKet Study: Reduction Of Chronic Post-surgical Pain with Ketamine

Professor Andrew Davidson (Vic)

T-REX Study: Neurodevelopmental outcome after sevoflurane versus dexmedetomidine/ remifentanil anaesthesia in infancy

Professor Professor Yahya Shehabi (Vic)

DiCE 1: Dexmedetomidine in High Risk Cardiac Surgery Evaluation

Professor Paul Myles (Vic)

ITACS Trial: IV iron for Treatment of Anaemia before Cardiac Surgery.


Professor Paul Myles (Vic)

EPICS-Australasia: Epidemiology of Critical care provision after Surgery


Dr Warren Pavey (WA)

Prothrombinex vs FFP for bleeding after cardiopulmonary bypass study

Professor Alan Merry (NZ)

Z- bugs trial: Apprehending micro-organisms injected during anaesthesia.

Professor David Story (Vic)

C-CaFe Trial: Colorectal cancer, anaemia and iron management

Professor Paul Myles (Vic)

CELSUS trial: high-dose dexamethasone in cardiac surgery

Professor Tomás Corcoran (WA) PADDI Trial: Perioperative ADministration of Dexamethasone and Infection trial 2014
Professor Paul Myles (Vic) Statins Before Surgery Study 3S 2014
Dr Richard Halliwell (NSW) International Surgical Outcomes Study (ISOS) 2013
Dr Doug Campbell (NZ) NeuroVISION Study: Neurological impact of vascular events in noncardiac surgery patients cohort evaluation study. 2013
Dr Mark Shulman (Vic) METS: Measurement of Exercise Tolerance for Surgery. 2013

Last updated 14:51 4.04.2024